As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents?

As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents?

As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents? 


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Stephen Nicholls, MD

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader Professor of Cardiology University of Adelaide Consultant Cardiologist Royal Adelaide Hospital Adelaide, Australia